Business
AYURCANN REPORTS RECORD SALES GROWTH IN Q3 2025 OF $14,179,974 AND PROVIDES CORPORATE UPDATE
Toronto, Ontario, May 16, 2025 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF) (“Ayurcann” or the “Company”) is excited to announce record-breaking financial results for the three months ended March 31, 2025, the highlights of which are included in this news release. As a leading player in the rapidly growing cannabis industry, Ayurcann continues to demonstrate exceptional growth and operational excellence, positioning itself for long-term success. All figures are reported
About this update from Ayurcann Holdings Corp.
[{"type":"image","alt":"Ayurcann Holdings Corp.","displaySize":"","headline":null,"caption":"Ayurcann Holdings Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":203,"height":191,"url":"https://media.zenfs.com/en/globenewswire.com/269152d55308912eddb9304883eacb65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WB2uH.vK1Y8HU7wcX7rNLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTMzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/269152d55308912eddb9304883eacb65","width":203,"height":191}},"lazy":false},{"type":"text","content":"Toronto, Ontario, May 16, 2025 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF) (“Ayurcann” or the “Company”) is excited to announce record-breaking financial results for the three months ended March 31, 2025, the highlights of which are included in this news release. As a leading player in the rapidly growing cannabis industry, Ayurcann continues to demonstrate exceptional growth and operational excellence, positioning itself for long-term success. All figures are reported in Canadian dollars. The Company’s full set of consolidated financial statements for the three months ended March 31, 2025 and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.ayurcann.com and its profile page on SEDAR+ at www.sedarplus.ca.","length":798,"tagName":"p"},{"type":"text","content":"Financial Highlights for the Three Months ending March 31, 2025: Executing with Consistency","length":91,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue Growth: Ayurcann generated $14,179,974 in gross revenue for Q3 2025, representing a 22% year-over-year increase (vs. $11,655,360 in Q3 2024). This continued growth reflects robust demand across our expanding product categories and successful national distribution efforts.","length":280,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":280,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Profitability: Ayurcann achieved positive adjusted EBITDA1 of $766,742 at the operating subsidiary level and $342,634 on a consolidated basis, with a healthy gross margin of 38%, reinforcing our disciplined focus on cost control and sustainable profitability.","length":259,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":259,"olType":false},{"type":"...